These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 33509418)

  • 1. Prevalence of high-risk drug use and coverage of opioid substitution treatment and needle and syringe programs in Lithuania in 2015-2016: A multi-method estimation study.
    Thanki D; Mravčík V; Běláčková V; Mačiulytė D; Zábranský T; Širvinskienė A; Subata E; Lorenzo-Ortega R
    J Subst Abuse Treat; 2021 Mar; 122():108229. PubMed ID: 33509418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review.
    Larney S; Peacock A; Leung J; Colledge S; Hickman M; Vickerman P; Grebely J; Dumchev KV; Griffiths P; Hines L; Cunningham EB; Mattick RP; Lynskey M; Marsden J; Strang J; Degenhardt L
    Lancet Glob Health; 2017 Dec; 5(12):e1208-e1220. PubMed ID: 29074410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis.
    Platt L; Minozzi S; Reed J; Vickerman P; Hagan H; French C; Jordan A; Degenhardt L; Hope V; Hutchinson S; Maher L; Palmateer N; Taylor A; Bruneau J; Hickman M
    Addiction; 2018 Mar; 113(3):545-563. PubMed ID: 28891267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs.
    Platt L; Minozzi S; Reed J; Vickerman P; Hagan H; French C; Jordan A; Degenhardt L; Hope V; Hutchinson S; Maher L; Palmateer N; Taylor A; Bruneau J; Hickman M
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD012021. PubMed ID: 28922449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings.
    Vickerman P; Martin N; Turner K; Hickman M
    Addiction; 2012 Nov; 107(11):1984-95. PubMed ID: 22564041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost-effectiveness of harm reduction.
    Wilson DP; Donald B; Shattock AJ; Wilson D; Fraser-Hurt N
    Int J Drug Policy; 2015 Feb; 26 Suppl 1():S5-11. PubMed ID: 25727260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of Injecting Drug Use and Coverage of Interventions to Prevent HIV and Hepatitis C Virus Infection Among People Who Inject Drugs in Canada.
    Jacka B; Larney S; Degenhardt L; Janjua N; Høj S; Krajden M; Grebely J; Bruneau J
    Am J Public Health; 2020 Jan; 110(1):45-50. PubMed ID: 31725310
    [No Abstract]   [Full Text] [Related]  

  • 8. Estimating the number of people who inject drugs and syringe coverage in Australia, 2005-2016.
    Kwon JA; Iversen J; Law M; Dolan K; Wand H; Maher L
    Drug Alcohol Depend; 2019 Apr; 197():108-114. PubMed ID: 30802734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage.
    Mathers BM; Degenhardt L; Ali H; Wiessing L; Hickman M; Mattick RP; Myers B; Ambekar A; Strathdee SA;
    Lancet; 2010 Mar; 375(9719):1014-28. PubMed ID: 20189638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modelling the impact of a national scale-up of interventions on hepatitis C virus transmission among people who inject drugs in Scotland.
    Fraser H; Mukandavire C; Martin NK; Goldberg D; Palmateer N; Munro A; Taylor A; Hickman M; Hutchinson S; Vickerman P
    Addiction; 2018 Nov; 113(11):2118-2131. PubMed ID: 29781207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal analysis of change in individual-level needle and syringe coverage amongst a cohort of people who inject drugs in Melbourne, Australia.
    O'Keefe D; Scott N; Aitken C; Dietze P
    Drug Alcohol Depend; 2017 Jul; 176():7-13. PubMed ID: 28463684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Global coverage of interventions to prevent and manage drug-related harms among people who inject drugs: a systematic review.
    Colledge-Frisby S; Ottaviano S; Webb P; Grebely J; Wheeler A; Cunningham EB; Hajarizadeh B; Leung J; Peacock A; Vickerman P; Farrell M; Dore GJ; Hickman M; Degenhardt L
    Lancet Glob Health; 2023 May; 11(5):e673-e683. PubMed ID: 36996860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High coverage needle/syringe programs for people who inject drugs in low and middle income countries: a systematic review.
    Des Jarlais DC; Feelemyer JP; Modi SN; Abdul-Quader A; Hagan H
    BMC Public Health; 2013 Jan; 13():53. PubMed ID: 23332005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Updates on syringe coverage and service uptake among needle and syringe programs in the United States, 2019-2020.
    Tookes HE; Bartholomew TS; Sugar SES; Plesons MD; Bluthenthal RN; Wenger LD; Patel SV; Kral AH; Lambdin BH
    Int J Drug Policy; 2024 Jan; 123():104289. PubMed ID: 38071932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe.
    Fraser H; Martin NK; Brummer-Korvenkontio H; Carrieri P; Dalgard O; Dillon J; Goldberg D; Hutchinson S; Jauffret-Roustide M; Kåberg M; Matser AA; Matičič M; Midgard H; Mravcik V; Øvrehus A; Prins M; Reimer J; Robaeys G; Schulte B; van Santen DK; Zimmermann R; Vickerman P; Hickman M
    J Hepatol; 2018 Mar; 68(3):402-411. PubMed ID: 29080808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of time of drug use according to needle and syringe program operating hours in Melbourne, Australia: Effects on individual-level needle and syringe coverage.
    O'Keefe D; Aitken C; Scott N; Dietze P
    Drug Alcohol Depend; 2018 Oct; 191():259-265. PubMed ID: 30153607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling the role of incarceration in HCV transmission and prevention amongst people who inject drugs in rural Kentucky.
    Stone J; Fraser H; Young AM; Havens JR; Vickerman P
    Int J Drug Policy; 2021 Feb; 88():102707. PubMed ID: 32151496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Syringe Coverage Among People Who Inject Drugs in West Virginia, USA.
    Allen ST; White RH; O'Rourke A; Schneider KE; Weir BW; Lucas GM; Kilkenny ME; Sherman SG
    AIDS Behav; 2021 Oct; 25(10):3377-3385. PubMed ID: 33886011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controlling HIV among people who inject drugs in Eastern Europe and Central Asia: insights from modeling.
    Vickerman P; Platt L; Jolley E; Rhodes T; Kazatchkine MD; Latypov A
    Int J Drug Policy; 2014 Nov; 25(6):1163-73. PubMed ID: 25449056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How does the use of multiple needles/syringes per injecting episode impact on the measurement of individual level needle and syringe program coverage?
    O'Keefe D; McCormack A; Cogger S; Aitken C; Burns L; Bruno R; Stafford J; Butler K; Breen C; Dietze P
    Int J Drug Policy; 2017 Aug; 46():99-106. PubMed ID: 28667880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.